Destiny Pharma has successfully tested a new antibiotic

The British company Destiny Pharma presented a compelling interim results of phase IIb studies of its experimental antibiotics, XF-73. During testing, the drug proved safe for human consumption, says PharmaTimes.

Destiny Pharma specializiruetsya on the creation of new options for treating nosocomial infections, which would help patients in the spread of drug resistance microorganisms. Platform XF allows to obtain compounds that destroy certain bacteria, including resistant strains.

In the current multicenter randomized blind placebo-controlled study evaluated the efficacy of an experimental drug in the prevention of postoperative bacterial infections including Staphylococcal aureus. Independent monitoring Board data, analyzing the collected the first 75 patients who had undergone surgical intervention on the heart, concluded that the safety of the medicine.

The study is expected to be completed by the end of 2020.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]